Navigation Links
QLT announces first quarter 2008 Visudyne(R) sales
Date:4/21/2008

VANCOUVER, April 21 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne(R) (verteporfin) product of US$36.5 million for the quarter ended March 31, 2008. This represents a decrease of 40.4% over sales in the first quarter of 2007. Sales in the U.S. were $9.3 million, up 10.6% from the prior-year first quarter, while sales outside the U.S. were $27.2 million, down 48.5% from the prior year. The drop in Visudyne sales was primarily due to the approval and reimbursement in Europe of alternative therapeutics for age-related macular degeneration.

QLT will release its full financial results on Friday, April 25, 2008, at 7:30 a.m. ET.

QLT Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies. Our research and development efforts are focused on pharmaceutical products in the fields of ophthalmology and dermatology. In addition, we utilize three unique technology platforms, photodynamic therapy, Atrigel(R) and punctal plugs with drugs, to create products such as Visudyne and Eligard(R) and future product opportunities. For more information, visit our web site at http://www.qltinc.com.

Conference call information

QLT Inc. will hold an investor conference call to discuss first quarter 2008 results on Friday, April 25 at 8:30 a.m. ET (5:30 a.m. PT). The call will be broadcast live via the Internet at http://www.qltinc.com. To participate on the call, please dial 1-800-319-4610 (North America) or 604-638-5340 (International) before 8:30 a.m. ET. A replay of the call will be available via the Internet and also via telephone at 1-800-319-6413 (North America) or 604-638-9010 (International), access code 7157, followed by the "#" sign.

A full explanation of how QLT determines and recognizes revenue resulting from Visudyne sales is contained in the financial statements contained in the periodic reports on Forms 10-Q and 10-K, under the heading "Significant Accounting Policies - Revenue Recognition." Visudyne sales are product sales by Novartis under its agreement with QLT.

QLT Plug Delivery, Inc. is a wholly-owned subsidiary of QLT Inc.

Atrigel is a registered trademark of QLT USA, Inc.

Visudyne is a registered trademark of Novartis AG.

Eligard is a registered trademark of Sanofi-aventis.

QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on The Toronto Stock Exchange under the trading symbol "QLT."

The Visudyne(R) sales figures in this press release are preliminary and unaudited and are not a complete disclosure of our quarterly financial results.

CONTACT: QLT Inc.: Vancouver, Canada, Therese Hayes, Telephone: (604) 707-7000 or 1-800-663-5486, Fax: (604) 707-7001; The Trout Group: New York, USA, Brandon Lewis, Telephone: (646) 378-2915 or Marcy Strickler, Telephone: (646) 378-2927


'/>"/>
SOURCE QLT Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Breckenridge Announces Approval of Generic Activella(R)
2. Accenx Technologies Announces New Leadership in Sales and Marketing Division
3. VNUS Medical Technologies, Inc. Announces the Hiring of Don Todd as Vice President of Marketing
4. CardiacAssist, Inc. Announces Five New TandemHeart Centers of Excellence
5. HeartWare Announces Move to an Expanded, Upgraded Manufacturing Facility
6. GHX Announces 2008 Best In Class Award Winners
7. AtriCure Announces Web Cast and Conference Call of First Quarter 2008 Financial Results
8. Huifeng Bio-Pharmaceutical (HFGB) Announces Participation in the 59th PHARMCHINA Expo
9. Zimmer Announces New Compliance Model
10. The Alliance for Lupus Research Announces 2008 Grantees
11. TeamStaff, Inc. Announces Results From Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... New York, NY (PRWEB) , ... May 04, ... ... country’s leading private owners, developers and operators of commercial real estate proudly announced ... its 2015 Heart Health initiative. Team members portfolio-wide will continue Olshan Properties’ ...
(Date:5/4/2016)... MD (PRWEB) , ... May 04, 2016 , ... ... Ostomy and Continence Nurses (WOCN) Society™ and Canadian Association for Enterostomal Therapy ... event promotion, time saving and planning tools to attendees and exhibitors for the ...
(Date:5/4/2016)... Gilmer, TX (PRWEB) , ... May 04, 2016 ... ... commencement of a master charity program created to assist the people of their ... working closely with nonprofit organizations and community leaders. Their hope is to bring ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... 2016. SS&A teamed up with one of the top website design companies to ... contains informative legal articles related to the law firm's main practice areas. These ...
(Date:5/4/2016)... ... 2016 , ... Nordic Naturals announces another breakthrough innovation—Omega Curcumin, ... synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 mg concentrated ... and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays a distinct ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 2016 According to market research ... Growth and Demand Forecast to 2022 - Industry Insights ... Field, Very High Field, Low to Mid Field, and ... Spine, Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, and ... (MRI) market was valued at $5,351.7 million in 2015, ...
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... 2016  Celsion Corporation (NASDAQ: CLSN ), ... from the first cohort of patients in its ... Study) combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... In the first three patients dosed, GEN-1 plus ...
Breaking Medicine Technology: